These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9531305

  • 1. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H, Shu S.
    J Immunol; 1998 Apr 01; 160(7):3444-52. PubMed ID: 9531305
    [Abstract] [Full Text] [Related]

  • 2. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 3. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
    Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S.
    Cancer Res; 1996 Oct 01; 56(19):4338-42. PubMed ID: 8813119
    [Abstract] [Full Text] [Related]

  • 4. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.
    Otolaryngol Head Neck Surg; 2001 Apr 01; 124(4):436-41. PubMed ID: 11283503
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy of Th1 and Th2 L-selectin--CD4+ tumor-reactive T cells.
    To WC, Seeley BM, Barthel SW, Shu S.
    Laryngoscope; 2000 Oct 15; 110(10 Pt 1):1648-54. PubMed ID: 11037819
    [Abstract] [Full Text] [Related]

  • 10. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS.
    J Immunol; 1994 Feb 01; 152(3):1277-88. PubMed ID: 8301131
    [Abstract] [Full Text] [Related]

  • 11. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1994 May 15; 54(10):2744-50. PubMed ID: 8168105
    [Abstract] [Full Text] [Related]

  • 12. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 13. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T, Krinock RA, Chang AE, Shu S.
    Cancer Res; 1993 Sep 15; 53(18):4315-21. PubMed ID: 8364926
    [Abstract] [Full Text] [Related]

  • 14. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep 15; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 15. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
    Hu HM, Urba WJ, Fox BA.
    J Immunol; 1998 Sep 15; 161(6):3033-41. PubMed ID: 9743368
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H, Li F, Gordon JR, Xiang J.
    Cancer Res; 2002 Apr 01; 62(7):2043-51. PubMed ID: 11929823
    [Abstract] [Full Text] [Related]

  • 18. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
    Plautz GE, Touhalisky JE, Shu S.
    Cell Immunol; 1997 Jun 15; 178(2):101-7. PubMed ID: 9225000
    [Abstract] [Full Text] [Related]

  • 19. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE.
    Cancer Res; 2005 Feb 01; 65(3):1063-70. PubMed ID: 15705908
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.